Overview

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication

Status:
Not yet recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
This is an open-label pilot trial to assess the safety and feasibility of a novel 6-week psilocybin-assisted psychotherapy intervention to facilitate successful tapering/discontinuation of opioid pain medication in adult patients receiving long-term opioid therapy for chronic pain. Participation will last approximately 8 months and includes two 25mg psilocybin-assisted psychotherapy sessions. The study will evaluate the incidence and severity of adverse events during and after treatment, the number of participants who drop out of the study for intervention-related reasons, and the self-reported benefits and harms of the intervention.
Phase:
Phase 2
Details
Lead Sponsor:
University of British Columbia
Collaborator:
EntheoTech Bioscience Inc.
Treatments:
Psilocybin